Form 8-K - Current report:
SEC Accession No. 0001193125-26-381879
Filing Date
2026-09-03
Accepted
2026-09-03 16:06:14
Documents
13
Period of Report
2026-08-31
Items
Item 3.03: Material Modifications to Rights of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d174614d8k.htm   iXBRL 8-K 26723
2 EX-4.1 d174614dex41.htm EX-4.1 192200
6 GRAPHIC g174614g0903081510818.jpg GRAPHIC 2585
  Complete submission text file 0001193125-26-381879.txt   381791

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA teva-20260831.xsd EX-101.SCH 3204
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE teva-20260831_lab.xml EX-101.LAB 17233
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE teva-20260831_pre.xml EX-101.PRE 10828
17 EXTRACTED XBRL INSTANCE DOCUMENT d174614d8k_htm.xml XML 3571
Mailing Address TEVA PHARMACEUTICAL INDUSTRIES LIMITED 124 DVORA HANEVI'A ST. TEL AVIV Israel
Business Address TEVA PHARMACEUTICAL INDUSTRIES LIMITED 124 DVORA HANEVI'A ST. TEL AVIV Israel 972 (3) 914-8213
TEVA PHARMACEUTICAL INDUSTRIES LTD (Filer) CIK: 0000818686 (see all company filings)

EIN.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-16174 | Film No.: 261358381
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)